Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

EphB4 inhibitor

DRUG CLASS:

EphB4 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

EGFR amplification	Glioblastoma	EGFR amplification	Glioblastoma	KD019 Sensitive: C2 – Inclusion Criteria KD019 Sensitive : C2	KD019 Sensitive: C2 – Inclusion Criteria KD019 Sensitive : C2
EFNB2 positive	Cholangiocarcinoma	EFNB2 positive	Cholangiocarcinoma	sEphB4-HSA Sensitive: C3 – Early Trials sEphB4-HSA Sensitive : C3	sEphB4-HSA Sensitive: C3 – Early Trials sEphB4-HSA Sensitive : C3
EFNB2 negative	Cholangiocarcinoma	EFNB2 negative	Cholangiocarcinoma	sEphB4-HSA Sensitive: C3 – Early Trials sEphB4-HSA Sensitive : C3	sEphB4-HSA Sensitive: C3 – Early Trials sEphB4-HSA Sensitive : C3
EFNB2 negative	Hepatocellular Cancer	EFNB2 negative	Hepatocellular Cancer	sEphB4-HSA Sensitive: C3 – Early Trials sEphB4-HSA Sensitive : C3	sEphB4-HSA Sensitive: C3 – Early Trials sEphB4-HSA Sensitive : C3
EFNB2 positive	Hepatocellular Cancer	EFNB2 positive	Hepatocellular Cancer	sEphB4-HSA Sensitive: C3 – Early Trials sEphB4-HSA Sensitive : C3	sEphB4-HSA Sensitive: C3 – Early Trials sEphB4-HSA Sensitive : C3
EPHB2 expression	Urothelial Cancer	EPHB2 expression	Urothelial Cancer	pembrolizumab + sEphB4-HSA Sensitive: C3 – Early Trials pembrolizumab + sEphB4-HSA Sensitive : C3	pembrolizumab + sEphB4-HSA Sensitive: C3 – Early Trials pembrolizumab + sEphB4-HSA Sensitive : C3
KDELR3 overexpression	Uveal Melanoma	KDELR3 overexpression	Uveal Melanoma	BHG712 Resistant: D – Preclinical BHG712 Resistant : D	BHG712 Resistant: D – Preclinical BHG712 Resistant : D
ZNF765 overexpression	Hepatocellular Cancer	ZNF765 overexpression	Hepatocellular Cancer	BHG712 Sensitive: D – Preclinical BHG712 Sensitive : D	BHG712 Sensitive: D – Preclinical BHG712 Sensitive : D